T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India, 2022-09-09 12:48 (857 d 13:35 ago) – Posting: # 23282
Views: 3,676

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,362 posts in 4,906 threads, 1,674 registered users;
127 visitors (0 registered, 127 guests [including 14 identified bots]).
Forum time: 01:24 CET (Europe/Vienna)

It is better to know some of the questions
than all of the answers.    James Thurber

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5